Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
Go back to Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease| (NASDAQ: BLTE) | Delayed: 147.07 +0.95 (0.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.12 | 52 Week High | $ | |||
| Open | $147.63 | 52 Week Low | $ | |||
| Day High | $150.00 | P/E | N/A | |||
| Day Low | $144.79 | EPS | $ | |||
| Volume | 172,446 | |||||
